NASDAQ:MLNT - Melinta Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.05 -0.40 (-6.20 %) (As of 07/17/2018 01:21 AM ET)Previous Close$6.45Today's Range$5.87 - $6.5052-Week Range$5.20 - $22.50Volume451,300 shsAverage Volume276,872 shsMarket Capitalization$202.33 millionP/E Ratio-0.28Dividend YieldN/ABeta1.33 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut. Receive MLNT News and Ratings via Email Sign-up to receive the latest news and ratings for MLNT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:MLNT CUSIP15130J10 Webmelinta.com Phone312-767-0291 Debt Debt-to-Equity Ratio0.53 Current Ratio1.48 Quick Ratio1.20 Price-To-Earnings Trailing P/E Ratio-0.28 Forward P/E Ratio-1.47 P/E GrowthN/A Sales & Book Value Annual Sales$33.86 million Price / Sales5.61 Cash FlowN/A Price / CashN/A Book Value$2.31 per share Price / Book2.62 Profitability EPS (Most Recent Fiscal Year)($21.86) Net Income$-58,910,000.00 Net Margins-327.21% Return on Equity-49.88% Return on Assets-28.93% Miscellaneous Employees300 Outstanding Shares31,370,000Market Cap$202.33 Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions What is Melinta Therapeutics' stock symbol? Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT." How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics, Inc. (NASDAQ:MLNT) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.27) by $0.32. The biotechnology company had revenue of $14.84 million for the quarter, compared to the consensus estimate of $13.13 million. Melinta Therapeutics had a negative net margin of 327.21% and a negative return on equity of 49.88%. View Melinta Therapeutics' Earnings History. When is Melinta Therapeutics' next earnings date? Melinta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Melinta Therapeutics. What price target have analysts set for MLNT? 8 brokers have issued 12-month target prices for Melinta Therapeutics' shares. Their forecasts range from $2.00 to $15.00. On average, they anticipate Melinta Therapeutics' share price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 0.8%. View Analyst Ratings for Melinta Therapeutics. What is the consensus analysts' recommendation for Melinta Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Melinta Therapeutics stock? Here are some recent quotes from research analysts about Melinta Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ". We are initiating coverage of Melinta’s stock with an Overweight rating and $15 PT. Upward earnings revisions and multiple expansion will drive the shares higher, in our view. We think a greater appreciation for the company’s four commercial, antibiotic drugs (Baxdela, and its growing pipeline (new drugs, international expansion, additional indications) will increase earnings estimates to levels not yet reflected in consensus expectations. Also, MLNT is considering adjacent opportunities, which means it could become a diversified hospital company. This should improve its trading multiple, in our view." (7/1/2018) 2. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (3/17/2018) Are investors shorting Melinta Therapeutics? Melinta Therapeutics saw a drop in short interest during the month of May. As of May 31st, there was short interest totalling 1,329,597 shares, a drop of 28.4% from the May 15th total of 1,857,164 shares. Based on an average trading volume of 894,565 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.9% of the shares of the stock are short sold. View Melinta Therapeutics' Current Options Chain. Who are some of Melinta Therapeutics' key competitors? Some companies that are related to Melinta Therapeutics include Inflarx (IFRX), AC Immune (ACIU), Kiniksa Pharmaceuticals (KNSA), CymaBay Therapeutics (CBAY), Rocket Pharmaceuticals (RCKT), Amphastar Pharmaceuticals (AMPH), NuCana (NCNA), AMAG Pharmaceuticals (AMAG), Eidos Therapeutics (EIDX), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Cara Therapeutics (CARA), Abeona Therapeutics (ABEO), Aptinyx (APTX) and ChemoCentryx (CCXI). Who are Melinta Therapeutics' key executives? Melinta Therapeutics' management team includes the folowing people: Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)Mr. Daniel Mark Wechsler, Pres & CEO (Age 50)Dr. Thomas A. Steitz Ph.D., Co-FounderDr. Peter B. Moore Ph.D., Co-FounderDr. William L. Jorgensen Ph.D., Co-Founder Has Melinta Therapeutics been receiving favorable news coverage? News articles about MLNT stock have trended somewhat negative recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Melinta Therapeutics earned a news sentiment score of -0.06 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.53 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. Who are Melinta Therapeutics' major shareholders? Melinta Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Pennsylvania Trust Co (0.85%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics. Which institutional investors are selling Melinta Therapeutics stock? MLNT stock was sold by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co. View Insider Buying and Selling for Melinta Therapeutics. How do I buy shares of Melinta Therapeutics? Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Melinta Therapeutics' stock price today? One share of MLNT stock can currently be purchased for approximately $6.05. How big of a company is Melinta Therapeutics? Melinta Therapeutics has a market capitalization of $202.33 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe. How can I contact Melinta Therapeutics? Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 312-767-0291 or via email at [email protected] MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 412 (Vote Outperform)Underperform Votes: 277 (Vote Underperform)Total Votes: 689MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?